Pharmasset Inc. said April 20 the development of its most advanced drug candidate, clevudine, will be halted because of concerns over severe muscle weakness. Hepatitis B patients enrolled in the late-stage QUASH studies in South Korea, trying the experimental drug, showed an alarming rate of myopathy cases. The firm will continue collecting safety data and monitoring patients after the study is discontinued.